Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574873 · ClinicalTrials.gov registry record · Phase 3
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 502
- Enrollment target
NCT00574873 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 502 participants.
The verdict
NCT00574873, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 502 participants
- Enrollment target
Study Summary
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.
Interventions
- DRUG Bosutinib
- DRUG imatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2008-02-05 |
| Est. Completion | 2015-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574873
The ClinicalTrials.gov registry entry for NCT00574873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 502 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bosutinib is the first listed.
NCT00574873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574873 about?
NCT00574873 is a clinical study titled "Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML". Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.
What is the current status of trial NCT00574873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 502 participants. The study started on 2008-02-05. Estimated completion is 2015-05-27.
What interventions are being tested in trial NCT00574873?
The interventions under investigation include: Bosutinib (DRUG), imatinib (DRUG).
Who is sponsoring clinical trial NCT00574873?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.